BioDelivery Sciences International Inc. (BDSI)

3.27
NASDAQ : Health Technology
Prev Close 3.27
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.70 / 4.14
Avg Volume 611.80K
Exchange NASDAQ
Shares Outstanding 70.69M
Market Cap 243.18M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Small Biotechs Turn on the Revenue Jets

3 Small Biotechs Turn on the Revenue Jets

BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Breaches Of Fiduciary Duty By BioDelivery Sciences International, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Breaches Of Fiduciary Duty By BioDelivery Sciences International, Inc.

Levi & Korsinsky announces it has commenced an investigation of BioDelivery Sciences International, Inc.

4 Small-Caps on My Earnings Watch List

4 Small-Caps on My Earnings Watch List

We are coming my favorite part of earnings season -- when these small-caps report.

3 Biotech Stocks on Readers' Minds

3 Biotech Stocks on Readers' Minds

We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.

Trump's FDA: A Friendlier Biotech Sheriff

Trump's FDA: A Friendlier Biotech Sheriff

There still will be winners and losers, but the new administration's FDA is a net plus for the industry.

2 Recovering Biotech Names With Room to Run

2 Recovering Biotech Names With Room to Run

There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.

4 Undervalued Biotech Stocks

4 Undervalued Biotech Stocks

Two are turnaround stories, and two are oversold.

2 Oversold Biopharmas With Big 2017 Upsides

2 Oversold Biopharmas With Big 2017 Upsides

Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

Endo International Is Top 'Dog of the S&P 500'

Endo International Is Top 'Dog of the S&P 500'

There are more dogs on the S&P 500 than on the Dow. Here's one example.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

3 Stocks for Growth in 2017

3 Stocks for Growth in 2017

BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.

TheStreet Quant Rating: D- (Sell)